

Special Issue

Personalized Medicine in Oral Cancer

Message from the Guest Editor

Oral cancer is a prevalent malignancy globally, especially in South-East Asia, and its incidence continues to climb according to the GLOBOCAN database and the World Health Organization. Radical surgery with or without adjuvant chemo-radiotherapy is the primary form of management for loco-regional oral squamous cell carcinoma (OSCC), the most common histologic type of oral cancer. While 80–90% of early OSCCs are cured, the prognosis for patients with advanced-stage OSCC remains poor. This Special Issue of the *Journal of Personalized Medicine* aims to explore the latest innovative findings in the translation research of oral cancer and provide promising solutions for this unmet need. Studies using basic science, clinical and population-based approaches, and focusing on, but not limited to, prognostic and therapeutic biomarkers, cancer metabolism, and the tumor microenvironment are encouraged to submit contributions. Our goal is to demonstrate the scientific advances in this field and pave the way towards personalized medicine for human health and wellness.

Guest Editor

Prof. Dr. Shyng-Shiou F Yuan

Graduate Institute of Medicine, Kaohsiung Medical University,
Kaohsiung City 80708, Taiwan

Deadline for manuscript submissions

closed (1 June 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 4.1
Indexed in PubMed



mdpi.com/si/83581

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2024).